Cagrilintide Acetate

Cas:1415456-99-3
Cagrilintide Acetate (AM833) is a long-acting amylin and calcitonin dual receptor agonist peptide developed by Novo Nordisk. It is a 37-amino-acid peptide with an intramolecular disulfide bond and C20 lipidation. The monotherapy remains investigational; its major development is the fixed-dose combination CagriSema with semaglutide for obesity and type 2 diabetes.